chenodeoxycholic acid has been researched along with Disease Models, Animal in 81 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 9 (11.11) | 18.7374 |
1990's | 3 (3.70) | 18.2507 |
2000's | 8 (9.88) | 29.6817 |
2010's | 48 (59.26) | 24.3611 |
2020's | 13 (16.05) | 2.80 |
Authors | Studies |
---|---|
Carino, A; Cipriani, S; D'Amore, C; De Marino, S; Festa, C; Finamore, C; Fiorucci, S; Monti, MC; Renga, B; Sepe, V; Zampella, A | 1 |
Balasubramaniyan, N; Devereaux, MW; Orlicky, DJ; Sokol, RJ; Suchy, FJ | 1 |
Dai, Z; Fernandez, JA; Griffin, JH; Huuskonen, MT; Lazic, D; Montagne, A; Nikolakopoulou, AM; Sagare, AP; Wang, Y; Zhao, Z; Zlokovic, BV | 1 |
Adorini, L; Brescia, P; Galbiati, M; Invernizzi, P; Mileti, E; Mouries, J; Penna, G; Rescigno, M; Silvestri, A; Sorribas, M; Spadoni, I; Wiest, R | 1 |
Feng, W; Hao, Z; Liu, Y; Ren, L; Song, Q; Zhang, L | 1 |
Chen, Q; Gai, Z; Gui, T; Guo, X; Liu, J; Ma, H | 1 |
Cui, S; Ge, C; Gonzalez, FJ; Guo, Y; Hao, H; He, Q; Huang, N; Pan, X; Wang, G; Wang, H; Zhang, P; Zhou, J | 1 |
Bian, Z; Ge, K; Han, X; Huang, F; Jia, W; Li, M; Qu, C; Rajani, C; Wang, S; Wei, M; Xie, G; Yang, W; Zhang, Y; Zhao, A; Zhao, L; Zheng, X | 1 |
Bi, Y; Cheng, W; Ding, J; Li, M; Ni, Z; Sun, S; Yu, C; Yu, J; Zhou, L | 1 |
Andersen, H; Divanovic, S; Haslam, DB; Horrigan, O; Jose, S; Madan, R; Moreno-Fernandez, ME; Mukherjee, A; Setchell, KDR; Sharma, D; Zhang, W | 1 |
Attema, J; Caspers, MPM; de Ruiter, C; Kleemann, R; Menke, AL; Radhakrishnan, S; Salic, K; van den Hoek, AM; van Nieuwkoop, A; Verschuren, L; Worms, N | 1 |
Chen, J; Chen, LF; Chiang, CM; Hu, X; Jung, H; Kemper, B; Kemper, JK; Sun, H; Wu, SY | 1 |
Iguchi, Y; Inoue, R; Ito, K; Okumura, A; Sakamoto, K; Takeuchi, JS; Umezawa, K; Une, M; Wakita, T; Watashi, K; Yamashita, Y; Yamauchi, T; Yoneda, M | 1 |
Chen, J; Han, Y; Li, L; Teufel, A; Wang, B; Weng, H; Wu, L; Yao, Y; Yue, S; Zheng, Z; Zhu, S | 1 |
Duan, Y; Gao, Y; Guo, D; He, L; Jiang, W; Jin, C; Lin, H; Qiu, W; Wang, L; Yang, R; Yao, J; Zhang, L; Zhou, Y | 1 |
Chen, J; Gu, X; Luo, H; Su, C; Tang, J; Xiao, L; Xiong, F; Zha, L; Zhao, Y; Zheng, Z | 1 |
Dan, J; Habuchi, H; Habuchi, O; Ikeuchi, M; Izumi, M; Takeuchi, K; Ushida, T | 1 |
Bowlus, C; Floreani, A; Gershwin, ME; Tanaka, A | 1 |
Afonso, MB; Borralho, PM; Carvalho, CC; Castro, RE; Cortez-Pinto, H; Duarte, A; Machado, MV; Rodrigues, CM; Rodrigues, PM; Simão, AL; Trindade, A | 1 |
Adorini, L; Aldini, R; Camborata, C; Cont, M; D'Errico, A; Degiovanni, A; Franco, P; Maroni, L; Roda, A; Spinozzi, S; Vasuri, F | 1 |
Claudel, T; Fuchs, CD; Scharnagl, H; Stojakovic, T; Trauner, M | 1 |
Andreone, P; Gitto, S; Guarneri, V; Sartini, A | 1 |
Briand, F; Brousseau, E; Burcelin, R; Quinsat, M; Sulpice, T | 1 |
Feigh, M; Gillum, MP; Hansen, HH; Jelsing, J; Kristiansen, MN; Rigbolt, KT; Tølbøl, KS; Veidal, SS; Vrang, N | 1 |
Blomenkamp, K; Greenspon, J; Guzman, MA; Heafner, N; Kakarla, V; Korremla, N; Kumar Jain, A; Manithody, C; Phillips, W; Pochampally, S; Price, A; Ratchford, T; Saxena, S; Villalona, G; Westrich, M | 1 |
Cremonesi, A; Gai, Z; Gui, T; Hartling, I; Häusler, S; Hiller, C; Kullak-Ublick, GA; Thasler, WE; Visentin, M; Zhao, L | 1 |
Asakawa, M; Goto, T; Itoh, M; Kai, T; Kanai, S; Ogawa, Y; Sakai, T; Shirakawa, I; Suganami, T; Yoneyama, T | 1 |
Adorini, L; Cellai, I; Comeglio, P; Corno, C; Filippi, S; Maggi, M; Morelli, A; Pini, A; Sarchielli, E; Vannelli, GB; Vignozzi, L | 1 |
Duan, Y; Li, B; Qin, H; Wei, M; Wu, X; Wu, Y; Xi, L; Zhang, F; Zhou, Y | 1 |
Chen, YH; Li, J; Luo, B; Song, J; Song, YP; Xie, DD; Xu, DX; Xu, S; Yu, DX; Zhang, ZH; Zhu, JB | 1 |
Alles, LK; Damink, SWO; de Haan, L; de Waart, DR; Ergin, B; Heger, M; Jansen, PL; Lionarons, DA; Maas, A; Olthof, PB; Reiniers, MJ; Schaap, FG; Uz, Z; van Golen, RF; van Gulik, TM; Verheij, J | 1 |
Chen, YH; Fei, J; Fu, L; Hu, B; Li, JB; Xu, DX; Zhao, H | 1 |
Adorini, L; Cellai, I; Comeglio, P; Corno, C; Filippi, S; Maggi, M; Morelli, A; Sarchielli, E; Vannelli, GB; Vignozzi, L | 1 |
Oda, S; Takeuchi, T; Tsuneyama, K; Yang, F; Yokoi, T | 1 |
Adorini, L; Feigh, M; Fensholdt, LKD; Hansen, HH; Jelsing, J; Nielsen, JC; Papazyan, R; Rigbolt, KTG; Roth, JD; Veidal, SS; Vrang, N; Young, M | 1 |
Adorini, L; Bellafante, E; Fan, HM; Jansen, E; Jones, P; Marchesi, JR; Marschall, HU; McDonald, JAK; McIlvride, S; Nikolova, V; Shapiro, D; Wahlström, A; Williamson, C | 1 |
Elst, IV; Farre, R; Klein, S; Komuta, M; Laleman, W; Nevens, F; Roskams, T; Trebicka, J; Vanuytsel, T; Verbeke, L; Windmolders, P | 1 |
DeMorrow, S; Frampton, G; Galindo, C; McMillin, M; Pae, HY; Quinn, M | 1 |
Eloranta, JJ; Gai, Z; Kullak-Ublick, GA; Mwinyi, J; Schaffner, CA; Thasler, WE | 1 |
Bonde, Y; Rudling, M | 1 |
Narala, VR; Narasimha, VR; Panati, K; Shaik, FB | 1 |
Chi, X; Lan, X; Li, C; Li, J; Weng, X | 1 |
Lian, F; Liang, L; Wang, Y; Wu, X; Xiao, Y; Xu, H; Yang, X | 1 |
Dong, J; He, CY; Miao, LY; Qin, CH; Yan, ZW; Zhao, CY | 1 |
Chen, D; Chen, W; Liu, HL; Wang, X; Wu, ZH; Zeng, TS; Zhang, HM; Zhang, ZZ | 1 |
Berends, FJ; Betzel, B; Hollman, DAA; Ijssennagger, N; Janssen, AWF; Janssen, IM; Kersten, S; Milona, A; Mokry, M; Ramos Pittol, JM; van Mil, SWC | 1 |
Farre, R; Govaere, O; Klein, S; Laleman, W; Mannaerts, I; Mazzone, M; Nevens, F; Schierwagen, R; Trebicka, J; van Grunsven, LA; Vander Elst, I; Verbeke, L; Wenes, M; Windmolders, P | 1 |
Ali, MS; Bishop-Bailey, D; Bye, AP; Dombrowicz, D; Dorchies, E; Flora, GD; Gibbins, JM; Kriek, N; Molendi-Coste, O; Moraes, LA; Sage, T; Sasikumar, P; Staels, B; Unsworth, AJ; Vaiyapuri, S | 1 |
Barn, V; Farrell, GC; Geoffrey Haigh, W; Haczeyni, F; Ioannou, GN; Leclercq, IA; Mridha, AR; Poekes, L; Teoh, NC; Wang, H; Yeh, MM | 1 |
Cai, W; Chen, Y; Gong, Z; Tian, C; Wang, P; Wu, J; Xu, C; Zhao, S; Zhou, J | 1 |
Ceulemans, LJ; De Hertogh, G; Decuypere, JP; Farré, R; Jochmans, I; Laleman, W; Lenaerts, K; Monbaliu, D; Nevens, F; Pirenne, J; Tack, J; Verbeke, L | 1 |
Adorini, L; Cellai, I; Comeglio, P; Corcetto, F; Corno, C; Filippi, S; Maggi, M; Maneschi, E; Morelli, A; Pini, A; Sarchielli, E; Vannelli, GB; Vignozzi, L | 1 |
Distrutti, E; Fiorucci, S; Mencarelli, A; Renga, B | 1 |
Burgermeister, E; Ebeling, M; Ebert, MP; Einwächter, H; Fan, L; Geisler, F; Hiber, M; Rauser, S; Röcken, C; Schmid, RM; Walch, A; Wright, MB; Xing, X | 1 |
Fujimoto, Y; Iida, T; Yasukawa, K | 1 |
Cipriani, S; Fiorucci, S; Mencarelli, A; Palladino, G | 1 |
Kratzer, A; Levi, M; Lewis, LB; Miyazaki, M; Miyazaki-Anzai, S; Ting, TC | 1 |
Adorini, L; Danese, S; Gadaleta, RM; Klomp, LW; Laverny, G; Moschetta, A; Murzilli, S; Oldenburg, B; Penna, G; Renooij, W; Schipper, ME; Siersema, PD; van Erpecum, KJ; van Mil, SW; Willemsen, EC | 1 |
Chen, J; Chen, M; Lian, F; Liang, L; Wang, Y; Xu, H; Yang, X; Ye, Y; Zhan, Z | 1 |
Baldelli, F; Bifulco, G; Cipriani, S; Fiorucci, S; Mencarelli, A; Zampella, A | 1 |
Adorini, L; Carini, M; Cellai, I; Comeglio, P; Filippi, S; Gacci, M; Maggi, M; Maneschi, E; Morelli, A; Piccinni, MP; Saad, F; Sarchielli, E; Serni, S; Vannelli, GB; Vignozzi, L | 1 |
Burrin, DG; Holst, JJ; Jain, AK; Moore, DD; Stoll, B | 1 |
Adorini, L; Carini, M; Cellai, I; Comeglio, P; Filippi, S; Gacci, M; Maggi, M; Maneschi, E; Morelli, A; Sarchielli, E; Vannelli, GB; Vignozzi, L; Yehiely-Cohen, R | 1 |
Hu, Z; Liu, B; Ren, L; Song, G; Wang, C | 1 |
Bouscarel, B; Ceryak, S; Doy, M; Fukushima, S; Honda, A; Ikegami, T; Matsuzaki, Y; Shoda, J; Tanaka, N; Yoshida, S | 1 |
Seyama, Y | 1 |
Alvarez, AR; Amigo, L; Ferrada, C; Galdames, L; Klein, A; Miquel, JF; Morales, MG; Quinones, V; Rigotti, A; Rio, MC; Tichauer, JE; Zanlungo, S | 1 |
Schwaier, A; van der Linden, J; Weis, HJ | 1 |
Mitschke, H; Sauer, HD; Thoma, G; Winkler, R | 1 |
Bertagnolli, MM; Bilinski, RT; Chadburn, A; Churchill, M; Dannenberg, AJ; Mahmoud, NN; Martucci, C; Mestre, JR | 1 |
Deleuran, B; Jakobsen, NO; Jensen, SL; Kristensen, JU; Larsen, CG; Lausten, SB; Osman, MO | 1 |
Lagoo, A; McMurray, RW; Suwannaroj, S | 1 |
Aki, H; Goto, M; Okamoto, Y; Yamamoto, M | 1 |
Eastwood, GL | 1 |
Bonorris, GG; Chung, A; Marks, JW; Pearlman, BJ; Phillips, MJ; Schoenfield, LJ; Vimadalal, S | 1 |
Baggenstoss, AH; Hofmann, AF; Lancaster, MC; Wease, DF; Webster, KH | 1 |
Ceryak, S; Fromm, H; Malavolti, M; Shehan, KL | 1 |
Jeynes, BJ | 1 |
Cohen, BI; Kuroki, S; McSherry, CK; Mosbach, EH | 1 |
Poncelet, PR; Thompson, AG | 1 |
Bell, S; Connor, WE; DenBesten, L; Safaie-Shirazi, S | 1 |
3 review(s) available for chenodeoxycholic acid and Disease Models, Animal
Article | Year |
---|---|
Geoepidemiology and changing mortality in primary biliary cholangitis.
Topics: Animals; Chenodeoxycholic Acid; Cholagogues and Choleretics; Disease Models, Animal; Drug Design; Fluorescent Antibody Technique, Indirect; Humans; Liver Cirrhosis, Biliary; Precision Medicine; Ursodeoxycholic Acid | 2017 |
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives.
Topics: Animals; Chenodeoxycholic Acid; Cholangitis, Sclerosing; Disease Models, Animal; Humans; Hypertension, Portal; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Treatment Outcome | 2018 |
Cholestanol metabolism, molecular pathology, and nutritional implications.
Topics: Animals; Calcium Channels; Cell Membrane; Chenodeoxycholic Acid; Cholestanetriol 26-Monooxygenase; Cholestanol; Cholesterol; Disease Models, Animal; Mice; Mutation; Rats; Steroid Hydroxylases; Xanthomatosis, Cerebrotendinous | 2003 |
78 other study(ies) available for chenodeoxycholic acid and Disease Models, Animal
Article | Year |
---|---|
Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.
Topics: Animals; Bile Acids and Salts; Chemistry Techniques, Synthetic; Cholanes; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; HEK293 Cells; Hep G2 Cells; Humans; Ligands; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Molecular Targeted Therapy; Pruritus; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Small Molecule Libraries; Structure-Activity Relationship | 2014 |
miR-199a-5p inhibits the expression of ABCB11 in obstructive cholestasis.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; Chenodeoxycholic Acid; Cholestasis; Disease Models, Animal; Gene Expression Regulation; Male; Mice; Mice, Knockout; MicroRNAs; Nuclear Receptor Co-Repressor 1 | 2021 |
Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C.
Topics: Animals; Blood-Brain Barrier; Chenodeoxycholic Acid; Corpus Callosum; Disease Models, Animal; Enzyme Activation; Fibrinolytic Agents; Humans; Ischemia; Male; Mice, Inbred C57BL; Neuroprotective Agents; Oligodendroglia; Protein C; Receptor, PAR-1; Receptors, Thrombin; Stroke; White Matter | 2022 |
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
Topics: Animals; Bacterial Translocation; Capillary Permeability; Chenodeoxycholic Acid; Diet, High-Fat; Disease Models, Animal; Dysbiosis; Gastrointestinal Microbiome; Inflammation; Insulin Resistance; Intestinal Mucosa; Liver; Mice; Non-alcoholic Fatty Liver Disease; Protective Agents | 2019 |
Probiotic Lactobacillus rhamnosus GG prevents progesterone metabolite epiallaopregnanolone sulfate-induced hepatic bile acid accumulation and liver injury.
Topics: Angiogenic Proteins; Animals; Bile Acids and Salts; Bilirubin; Chenodeoxycholic Acid; Cholestasis; Cholesterol 7-alpha-Hydroxylase; Cholic Acid; Cytokines; Disease Models, Animal; Gastrointestinal Microbiome; Inflammation; Lacticaseibacillus rhamnosus; Liver; Male; Mice; Mice, Inbred C57BL; Pregnanolone; Probiotics; RNA-Binding Proteins; Signal Transduction; Ursodeoxycholic Acid | 2019 |
Farnesoid X Receptor (FXR) Aggravates Amyloid-β-Triggered Apoptosis by Modulating the cAMP-Response Element-Binding Protein (CREB)/Brain-Derived Neurotrophic Factor (BDNF) Pathway In Vitro.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Brain; Brain-Derived Neurotrophic Factor; Cell Line; Chenodeoxycholic Acid; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Hippocampus; Humans; Mice; Neurons; Receptors, Cytoplasmic and Nuclear; Signal Transduction | 2019 |
SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
Topics: Animals; Cells, Cultured; Chenodeoxycholic Acid; Disease Models, Animal; Drug Therapy, Combination; Hepatic Stellate Cells; Humans; Lipid Droplets; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Perilipin-1; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; Sumoylation; Transcriptional Activation; Treatment Outcome | 2020 |
A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility.
Topics: Adipose Tissue, Brown; Animals; Body Mass Index; Chenodeoxycholic Acid; Cholestenones; Clostridiales; Cohort Studies; Diet, High-Fat; Disease Models, Animal; Disease Susceptibility; Gastrointestinal Microbiome; Gene Expression Regulation; Glucagon-Like Peptide 1; Humans; Ileum; Lithocholic Acid; Male; Metagenomics; Mice; Mice, Inbred C57BL; Obesity; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Uncoupling Protein 1; Ursodeoxycholic Acid | 2020 |
Correlation of fecal metabolomics and gut microbiota in mice with endometriosis.
Topics: alpha-Linolenic Acid; Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Disease Models, Animal; Dysbiosis; Endometriosis; Feces; Female; Gastrointestinal Microbiome; Humans; Metabolomics; Mice; Mice, Inbred C57BL; RNA, Ribosomal, 16S | 2020 |
Obeticholic acid ameliorates severity of Clostridioides difficile infection in high fat diet-induced obese mice.
Topics: Animals; Anticholesteremic Agents; Chenodeoxycholic Acid; Clostridioides difficile; Clostridium Infections; Diet, High-Fat; Disease Models, Animal; Disease Progression; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; RNA-Binding Proteins | 2021 |
A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.
Topics: Animals; Atherosclerosis; Chenodeoxycholic Acid; Diet, High-Fat; Disease Models, Animal; Fast Foods; Hyperinsulinism; Hyperlipidemias; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Receptors, LDL; Transcriptome; Treatment Outcome | 2020 |
BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Topics: Animals; Azepines; Bile Acids and Salts; Cell Cycle Proteins; Chenodeoxycholic Acid; Cholestasis; Cholesterol 7-alpha-Hydroxylase; Disease Models, Animal; Drug Interactions; Gene Knockdown Techniques; Humans; Liver; Liver Cirrhosis, Biliary; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; NF-kappa B; Nuclear Proteins; Nuclear Receptor Co-Repressor 2; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Triazoles | 2020 |
Dual Agonist of Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo.
Topics: Animals; Antiviral Agents; Bile Acids and Salts; Chenodeoxycholic Acid; Cholic Acids; Disease Models, Animal; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Mice; Organic Anion Transporters, Sodium-Dependent; Prospective Studies; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Symporters; Transplantation Chimera; Virus Internalization | 2021 |
Obeticholic Acid Inhibits Anxiety via Alleviating Gut Microbiota-Mediated Microglia Accumulation in the Brain of High-Fat High-Sugar Diet Mice.
Topics: Animals; Anxiety; Behavior, Animal; Brain; Chenodeoxycholic Acid; Diet, High-Fat; Disease Models, Animal; Gastrointestinal Microbiome; Male; Mice; Mice, Inbred C57BL; Microglia; Sugars | 2021 |
Obeticholic Acid Derivative, T-2054 Suppresses Osteoarthritis via Inhibiting NF-κB-Signaling Pathway.
Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Cartilage; Cell Line; Cell Survival; Chenodeoxycholic Acid; Cytokines; Disease Models, Animal; Gene Expression Regulation; Inflammation Mediators; Lipopolysaccharides; Male; Mice; NF-kappa B; Nitric Oxide; Osteoarthritis; RAW 264.7 Cells; Signal Transduction | 2021 |
Soyasaponin A
Topics: Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Choline Deficiency; Colon; Diet; Disease Models, Animal; Gastrointestinal Microbiome; Inflammation; Liver; Male; Methionine; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Saponins | 2021 |
Bone marrow derived mast cells injected into the osteoarthritic knee joints of mice induced by sodium monoiodoacetate enhanced spontaneous pain through activation of PAR2 and action of extracellular ATP.
Topics: Adenosine Triphosphate; Animals; Arthritis, Experimental; Bone Marrow Cells; Chemokine CXCL2; Chenodeoxycholic Acid; Chronic Pain; Disease Models, Animal; Knee Joint; Male; Mast Cells; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Transgenic; Oligopeptides; Receptor, PAR-2; Receptors, Purinergic; Synovial Fluid | 2021 |
miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.
Topics: Animals; Apoptosis; Chenodeoxycholic Acid; Disease Models, Animal; Fast Foods; Inflammation; Liver Cirrhosis; Male; Mice; Mice, Knockout; MicroRNAs; Non-alcoholic Fatty Liver Disease; PPAR alpha; Receptors, Cytoplasmic and Nuclear | 2017 |
Metabolic Profile of Obeticholic Acid and Endogenous Bile Acids in Rats with Decompensated Liver Cirrhosis.
Topics: Animals; Bile Acids and Salts; Biliary Fistula; Chenodeoxycholic Acid; Disease Models, Animal; Feces; Intestinal Mucosa; Intestines; Liver; Liver Cirrhosis; Male; Metabolome; Metabolomics; Rats, Wistar; Tissue Distribution | 2017 |
FXR controls CHOP expression in steatohepatitis.
Topics: Animals; Binding Sites; Chenodeoxycholic Acid; Diet, High-Fat; Disease Models, Animal; Gene Expression Regulation; Glucose; Hep G2 Cells; Humans; Lipid Metabolism; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Promoter Regions, Genetic; Protein Binding; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors; RNA, Messenger; Signal Transduction; Transcription Factor CHOP; Tretinoin | 2017 |
Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
Topics: Animals; Body Weight; CD36 Antigens; Chenodeoxycholic Acid; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Diet; Disease Models, Animal; Dyslipidemias; Gene Expression Regulation; Insulin Resistance; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats; Receptors, LDL | 2018 |
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Topics: Animals; Biopsy; Chalcones; Chenodeoxycholic Acid; Collagen Type I; Collagen Type I, alpha 1 Chain; Diet, High-Fat; Disease Models, Animal; Galectin 3; Lipid Metabolism; Liraglutide; Liver; Liver Cirrhosis; Male; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Propionates; Time Factors; Weight Gain | 2018 |
No Gut No Gain! Enteral Bile Acid Treatment Preserves Gut Growth but Not Parenteral Nutrition-Associated Liver Injury in a Novel Extensive Short Bowel Animal Model.
Topics: Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Cholestasis; Cholesterol 7-alpha-Hydroxylase; Disease Models, Animal; Fibroblast Growth Factors; Gastrointestinal Tract; Intestine, Small; Liver; Liver Diseases; Parenteral Nutrition; Parenteral Nutrition, Total; Polymerase Chain Reaction; Receptor, Fibroblast Growth Factor, Type 4; Receptors, Cytoplasmic and Nuclear; Short Bowel Syndrome; Swine | 2018 |
Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.
Topics: Animals; Arachidonic Acid; Cell Movement; Cells, Cultured; Chenodeoxycholic Acid; Cytochrome P-450 Enzyme System; Diet, High-Fat; Disease Models, Animal; Female; Gene Expression Regulation; Hepatocytes; Humans; Lipid Metabolism; Mice; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Signal Transduction; THP-1 Cells | 2018 |
Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
Topics: Animals; Body Weight; Cell Death; Chenodeoxycholic Acid; Cytoprotection; Disease Models, Animal; Disease Progression; Gene Knockout Techniques; Hepatocytes; Insulin Resistance; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Receptor, Melanocortin, Type 4; Tumor Suppressor Protein p53 | 2018 |
Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model.
Topics: Animals; Antibiotics, Antineoplastic; Biomarkers; Bleomycin; Chenodeoxycholic Acid; Disease Models, Animal; Epithelial-Mesenchymal Transition; Male; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley | 2019 |
The ileum-liver Farnesoid X Receptor signaling axis mediates the compensatory mechanism of 17α-ethynylestradiol-induced cholestasis via increasing hepatic biosynthesis of chenodeoxycholic acids in rats.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; Cell Line; Chenodeoxycholic Acid; Cholestanetriol 26-Monooxygenase; Cholestasis, Intrahepatic; Cholesterol 7-alpha-Hydroxylase; Disease Models, Animal; Ethinyl Estradiol; Humans; Ileum; Liver; Male; Molecular Docking Simulation; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Steroid 12-alpha-Hydroxylase; Up-Regulation | 2018 |
Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury.
Topics: Acute Kidney Injury; Administration, Oral; Animals; Chenodeoxycholic Acid; Disease Models, Animal; Humans; Kidney; Lipopolysaccharides; Male; Mice; Mice, Inbred ICR; Nephritis; Oxidative Stress; Receptors, Cytoplasmic and Nuclear | 2018 |
FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; cdc25 Phosphatases; Chenodeoxycholic Acid; Cholestasis; Cyclin D1; Disease Models, Animal; Fibroblast Growth Factors; Gene Expression Regulation; Liver Regeneration; Male; Organ Size; Rats | 2018 |
Obeticholic acid alleviate lipopolysaccharide-induced acute lung injury via its anti-inflammatory effects in mice.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Chenodeoxycholic Acid; Disease Models, Animal; Humans; Inflammation; Lipopolysaccharides; Lung; Male; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; NF-kappa B; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Tumor Necrosis Factor-alpha | 2019 |
Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Chenodeoxycholic Acid; Disease Models, Animal; Hypertension, Pulmonary; Male; Monocrotaline; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear | 2019 |
Experimental Evidence of Liver Injury by BSEP-Inhibiting Drugs With a Bile Salt Supplementation in Rats.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; Chemical and Drug Induced Liver Injury; Chenodeoxycholic Acid; Disease Models, Animal; Drug Synergism; Female; Ketoconazole; Liver; Liver Function Tests; Rats, Sprague-Dawley | 2019 |
Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.
Topics: Animals; Biopsy; Chalcones; Chenodeoxycholic Acid; Disease Models, Animal; Liver Cirrhosis; Mice; PPAR alpha; Proof of Concept Study; Propionates; Transcription, Genetic | 2019 |
Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes.
Topics: Animals; Blood Glucose; Chenodeoxycholic Acid; Diabetes, Gestational; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Female; Glucose Intolerance; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Pregnancy; Pregnancy Complications | 2019 |
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.
Topics: Animals; Chenodeoxycholic Acid; Disease Models, Animal; Down-Regulation; Drug Evaluation, Preclinical; Hypertension, Portal; Liver Cirrhosis; Male; Nitric Oxide Synthase Type III; Random Allocation; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Signal Transduction | 2014 |
Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms.
Topics: Aminoquinolines; Animals; Bile Ducts; Blood-Brain Barrier; Chenodeoxycholic Acid; Cholestasis; Deoxycholic Acid; Disease Models, Animal; Endothelial Cells; Ligation; Male; Microvessels; Occludin; Permeability; Phosphorylation; Pyrimidines; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tight Junctions; Tissue Culture Techniques; Zonula Occludens-1 Protein; Zonula Occludens-2 Protein | 2014 |
The organic solute transporters alpha and beta are induced by hypoxia in human hepatocytes.
Topics: Animals; Binding Sites; Cell Hypoxia; Cell Line; Chenodeoxycholic Acid; Disease Models, Animal; Hepatocytes; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Failure, Chronic; Liver; Membrane Transport Proteins; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Response Elements; RNA Interference; Transfection; Up-Regulation | 2015 |
Stimulation of apical sodium-dependent bile acid transporter expands the bile acid pool and generates bile acids with positive feedback properties.
Topics: Ampicillin; Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Cholesterol 7-alpha-Hydroxylase; Cholic Acid; Cholic Acids; Deoxycholic Acid; Disease Models, Animal; Feedback, Physiological; Humans; Mice; Mice, Knockout; Organic Anion Transporters, Sodium-Dependent; Phenotype; Receptors, Cytoplasmic and Nuclear; Symporters | 2015 |
Chenodeoxycholic acid attenuates ovalbumin-induced airway inflammation in murine model of asthma by inhibiting the T(H)2 cytokines.
Topics: Animals; Asthma; Base Sequence; Bronchitis; Chenodeoxycholic Acid; Cytokines; Disease Models, Animal; DNA Primers; Female; Mice; Mice, Inbred BALB C; Ovalbumin; Th2 Cells | 2015 |
Farnesoid X receptor agonist CDCA reduces blood pressure and regulates vascular tone in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Chenodeoxycholic Acid; Disease Models, Animal; Endothelin-1; Hypertension; Mesenteric Arteries; NF-kappa B; Nitric Oxide Synthase; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Vascular Cell Adhesion Molecule-1; Vasoconstriction; Vasodilation | 2015 |
Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis.
Topics: Alanine Transaminase; Animals; Apoptosis; Aspartate Aminotransferases; Caspase 3; Chenodeoxycholic Acid; Concanavalin A; Disease Models, Animal; Fas Ligand Protein; fas Receptor; Female; Gastrointestinal Agents; Gene Expression Regulation; Hepatitis, Autoimmune; Hepatocytes; Interferon-gamma; Interleukin-2; Interleukin-4; Liver; Mice; Mice, Inbred C57BL; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Tumor Necrosis Factor-alpha | 2015 |
Therapeutic Effect of Chenodeoxycholic Acid in an Experimental Rabbit Model of Osteoarthritis.
Topics: Animals; Anterior Cruciate Ligament; Cartilage, Articular; Chenodeoxycholic Acid; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Femur; Injections, Intra-Articular; Interleukin-1beta; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Osteoarthritis; Prostaglandins E; Rabbits; Synovial Membrane; X-Ray Microtomography | 2015 |
Beneficial effect of farnesoid X receptor activation on metabolism in a diabetic rat model.
Topics: Animals; Body Weight; Chenodeoxycholic Acid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Gluconeogenesis; Glucose-6-Phosphatase; Liver; Male; Phosphoenolpyruvate Carboxykinase (ATP); Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors | 2016 |
Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Topics: Animals; Chenodeoxycholic Acid; Disease Models, Animal; DNA; Gene Expression Profiling; Gene Expression Regulation; Humans; Liver; Male; Mice; Mice, Inbred C57BL; Microarray Analysis; Non-alcoholic Fatty Liver Disease; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Transcriptional Activation | 2016 |
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Topics: Animals; Apoptosis; Biomarkers; Cell Cycle; Cell Line; Cell Proliferation; Chenodeoxycholic Acid; Cytokines; Disease Models, Animal; Endothelial Cells; Hemodynamics; Hepatic Stellate Cells; Hepatocytes; Humans; Inflammation; Inflammation Mediators; Kupffer Cells; Lipopolysaccharides; Liver; Liver Cirrhosis; Male; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Portal Pressure; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Thioacetamide; Tumor Necrosis Factor-alpha; Up-Regulation; Vascular Resistance | 2016 |
Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets.
Topics: Animals; Blood Platelets; Calcium Signaling; Chenodeoxycholic Acid; Cyclic GMP; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinogen; Genotype; Hemostasis; Humans; Isoxazoles; Ligands; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Cytoplasmic and Nuclear; Thrombosis; Time Factors | 2016 |
Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice.
Topics: Adiposity; Animals; Chenodeoxycholic Acid; Diet, Atherogenic; Disease Models, Animal; Fatty Liver; Female; Inflammation; Liver; Mice; Mice, Inbred NOD; Mice, Obese; Obesity; Weight Gain | 2017 |
Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis.
Topics: Adenosine Triphosphate; Animals; Bile Ducts; Caspase 3; Caspase Inhibitors; Cell Line; Chemical and Drug Induced Liver Injury; Chenodeoxycholic Acid; Cholestasis; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Inflammasomes; Interleukin-1beta; Kupffer Cells; Ligation; Liver; Liver Cirrhosis; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Potassium; Reactive Oxygen Species; Receptors, G-Protein-Coupled; RNA Interference; Signal Transduction; Transfection | 2016 |
Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats.
Topics: Animals; Apoptosis; Autophagy; Biomarkers; Chenodeoxycholic Acid; Disease Models, Animal; Endotoxins; Ileum; Inflammation Mediators; Intestinal Mucosa; Intestines; Male; Permeability; Rats; Receptors, Cytoplasmic and Nuclear; Reperfusion Injury; Signal Transduction | 2017 |
Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis.
Topics: Airway Remodeling; Animals; Bleomycin; Chenodeoxycholic Acid; Collagen; Disease Models, Animal; Fibrosis; Gene Expression Profiling; Immunohistochemistry; Inflammation; Lung; Male; Pulmonary Alveoli; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Ventricular Remodeling | 2017 |
Antiatherosclerotic effect of farnesoid X receptor.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cardiovascular Agents; CD11b Antigen; CD36 Antigens; Chenodeoxycholic Acid; Disease Models, Animal; DNA-Binding Proteins; Female; Humans; Hyperlipidemias; Interleukin-1beta; Interleukin-6; Ligands; Lipids; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR gamma; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Toll-Like Receptor 4; Transcription Factors; Tumor Necrosis Factor-alpha | 2009 |
Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy.
Topics: Animals; Cell Line; Cell Line, Tumor; Chenodeoxycholic Acid; Disease Models, Animal; DNA-Binding Proteins; Female; Hepatocytes; Hepatomegaly; Homeodomain Proteins; Humans; Hypertrophy; Introns; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2009 |
Relative inhibitory activity of bile acids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation, and chenodeoxycholic acid inhibition of tumour promotion in mouse skin two-stage carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Bile Acids and Salts; Carcinogens; Chenodeoxycholic Acid; Disease Models, Animal; Edema; Female; Indomethacin; Inflammation; Inhibitory Concentration 50; Mice; Mice, Inbred ICR; Neoplasms, Experimental; Skin Neoplasms; Structure-Activity Relationship; Tetradecanoylphorbol Acetate | 2009 |
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.
Topics: Animals; Chenodeoxycholic Acid; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Gene Expression Regulation; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Male; Muscle, Skeletal; Obesity; Phosphorylation; Random Allocation; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors | 2010 |
Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease.
Topics: Animals; Aorta; Apolipoproteins E; Calcinosis; Cattle; Cell Differentiation; Cells, Cultured; Chenodeoxycholic Acid; Chronic Disease; Disease Models, Animal; Kidney Diseases; Male; Mice; Mice, Knockout; Osteogenesis; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Triglycerides; Vascular Diseases | 2010 |
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.
Topics: Animals; Caco-2 Cells; Chenodeoxycholic Acid; Colon; Cytokines; Dextran Sulfate; Disease Models, Animal; Drug Evaluation, Preclinical; Gene Expression Regulation; Humans; Ileum; Inflammation Mediators; Inflammatory Bowel Diseases; Intestinal Absorption; Mice; Mice, Inbred C57BL; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha | 2011 |
Activation of farnesoid X receptor attenuates liver injury in systemic lupus erythematosus.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Aspartate Aminotransferases; Case-Control Studies; Chemical and Drug Induced Liver Injury; Chenodeoxycholic Acid; Concanavalin A; Cytoprotection; Disease Models, Animal; Female; Humans; Inflammation Mediators; Interferon-gamma; Interleukin-6; Liver; Lupus Erythematosus, Systemic; Mice; Mice, Inbred BALB C; Mice, Inbred MRL lpr; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Time Factors; Tumor Necrosis Factor-alpha | 2012 |
Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.
Topics: Animals; Chenodeoxycholic Acid; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Hypoglycemic Agents; Liver Diseases; Metabolic Diseases; Receptors, Cytoplasmic and Nuclear | 2011 |
Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit.
Topics: Androgens; Animals; Biomarkers; Chenodeoxycholic Acid; Dietary Fats; Disease Models, Animal; Drug Evaluation, Preclinical; Estradiol; Fibrosis; Male; Metabolic Syndrome; Prostate; Prostatitis; Rabbits; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger; Testosterone | 2012 |
Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs.
Topics: Animals; Animals, Newborn; Atrophy; Chenodeoxycholic Acid; Cholestasis; Disease Models, Animal; Fibroblast Growth Factors; Glucagon-Like Peptides; Intestinal Mucosa; Liver Diseases; Parenteral Nutrition, Total; Swine; Treatment Outcome | 2012 |
Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome.
Topics: Androgens; Animals; Blood Glucose; Cell Movement; Chenodeoxycholic Acid; Cholesterol; Diet, High-Fat; Disease Models, Animal; Hypogonadism; Male; Metabolic Syndrome; Muscle Contraction; Myocytes, Smooth Muscle; Prostate; Rabbits; Receptors, Androgen; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Testosterone; Triglycerides; Triptorelin Pamoate; Urinary Bladder | 2012 |
Effect of chenodeoxycholic acid on fibrosis, inflammation and oxidative stress in kidney in high-fructose-fed Wistar rats.
Topics: Animals; Biomarkers; Chenodeoxycholic Acid; Cytokines; Dietary Carbohydrates; Disease Models, Animal; Fibrosis; Fructose; Kidney; Lipid Metabolism; Male; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Nephritis; Oxidative Stress; Plasminogen Activator Inhibitor 1; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Transforming Growth Factor beta1 | 2012 |
Selective inhibition of CYP27A1 and of chenodeoxycholic acid synthesis in cholestatic hamster liver.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Bile; Chenodeoxycholic Acid; Cholestanetriol 26-Monooxygenase; Cholestasis; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cricetinae; Cytochrome P-450 CYP3A; Disease Models, Animal; Down-Regulation; Liver; Microsomes, Liver; Models, Chemical; Oxidoreductases, N-Demethylating; RNA, Messenger; Steroid 12-alpha-Hydroxylase; Steroid Hydroxylases | 2002 |
Overexpression of the cholesterol-binding protein MLN64 induces liver damage in the mouse.
Topics: Adenoviridae; Alkaline Phosphatase; Animals; Apoptosis; Cell Line; Chemical and Drug Induced Liver Injury; Chenodeoxycholic Acid; CHO Cells; Cholesterol; Cricetinae; Cricetulus; Disease Models, Animal; Gene Expression Regulation; Humans; Liver; Liver Diseases; Mice; Mice, Inbred C57BL; Phenotype; Phosphoproteins; Transfection | 2007 |
Tupaias (tree shrews) -- a new animal model for gallstone research. III. Cholesterol metabolism under different diets and CDCA.
Topics: Animals; Bile; Chenodeoxycholic Acid; Cholelithiasis; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Female; Intestinal Absorption; Liver; Tupaiidae | 1980 |
[Promotion of adenocarcinomas at the preternatural anus by bile acids in rats (author's transl)].
Topics: Adenocarcinoma; Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Cocarcinogenesis; Colon; Colonic Neoplasms; Colostomy; Disease Models, Animal; Intestinal Polyps; Neoplasms, Experimental; Rats; Time Factors | 1980 |
Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; beta Catenin; Carcinogenicity Tests; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cytoskeletal Proteins; Dinoprostone; Disease Models, Animal; Duodenal Neoplasms; Duodenum; Female; Mice; Trans-Activators | 1999 |
Graded experimental acute pancreatitis: monitoring of a renewed rabbit model focusing on the production of interleukin-8 (IL-8) and CD11b/CD18.
Topics: Acute Disease; Amylases; Animals; Ascites; CD11 Antigens; CD18 Antigens; Chenodeoxycholic Acid; Cholagogues and Choleretics; Disease Models, Animal; Hyperglycemia; Hypocalcemia; Interleukin-8; Laparotomy; Leukopenia; Ligation; Lipase; Necrosis; Neutrophils; Pancreas; Pancreatic Ducts; Pancreatitis; Rabbits; Respiratory Distress Syndrome; Sodium Chloride; Tumor Necrosis Factor-alpha; Up-Regulation | 1999 |
Suppression of renal disease and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acid.
Topics: Albuminuria; Animals; Antibodies, Antinuclear; Blood Urea Nitrogen; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cytokines; Disease Models, Animal; Female; Gastrointestinal Agents; Hemocyanins; Immunization; Immunoglobulin G; Kidney; Liver; Lupus Nephritis; Mice; Mice, Inbred NZB; Spleen; Survival Rate; Uremia; Urodynamics; Ursodeoxycholic Acid | 2001 |
Anti-inflammatory effects of 5-aminosalicylic acid conjugates with chenodeoxycholic acid and ursodeoxycholic acid on carrageenan-induced colitis in guinea-pigs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chenodeoxycholic Acid; Colitis, Ulcerative; Disease Models, Animal; Guinea Pigs; Mesalamine; Ursodeoxycholic Acid | 2001 |
Failure of cholestyramine to prevent bile salt injury to mouse gastric mucosa.
Topics: Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Cholestyramine Resin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gastric Mucosa; Gastritis; Hydrochloric Acid; Hydrogen-Ion Concentration; In Vitro Techniques; Male; Mice; Stomach Ulcer; Taurocholic Acid | 1975 |
Cholesterol gallstone formation and prevention by chenodeoxycholic and ursodeoxycholic acids. A new hamster model.
Topics: Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Cholelithiasis; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholesterol, Dietary; Cricetinae; Deoxycholic Acid; Disease Models, Animal; Female; Hydroxymethylglutaryl CoA Reductases; Liver; Mesocricetus | 1979 |
Influence of primary bile acid feeding on cholesterol metabolism and hepatic function in the rhesus monkey.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Bile; Bile Acids and Salts; Biopsy; Chenodeoxycholic Acid; Cholelithiasis; Cholesterol; Cholic Acids; Deoxycholic Acid; Diet; Disease Models, Animal; Lithocholic Acid; Liver; Liver Function Tests; Macaca mulatta | 1975 |
Effects of bile acid depletion and of ursodeoxycholic and chenodeoxycholic acids on biliary protein secretion in the hamster.
Topics: Animals; Bile; Bile Acids and Salts; Biliary Fistula; Chenodeoxycholic Acid; Cholic Acid; Cholic Acids; Chromatography, Gas; Cricetinae; Deoxycholic Acid; Disease Models, Animal; Lithocholic Acid; Male; Mesocricetus; Proteins; Ursodeoxycholic Acid | 1990 |
Treatment of experimentally induced cerebral atherothromboembolism in an animal model with streptokinase and taurochenodeoxycholate.
Topics: Animals; Chenodeoxycholic Acid; Disease Models, Animal; Intracranial Embolism and Thrombosis; Male; Rabbits; Streptokinase; Taurochenodeoxycholic Acid; Thromboembolism | 1988 |
Dissolution of cholesterol gallstones by bile acids in the prairie dog.
Topics: Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Cholelithiasis; Cholesterol; Disease Models, Animal; Hydroxymethylglutaryl CoA Reductases; Male; Sciuridae; Ursodeoxycholic Acid | 1988 |
Role of infected bile in spasm of the sphincter of oddi.
Topics: Ampulla of Vater; Animals; Bile; Bile Acids and Salts; Biliary Tract Diseases; Cats; Chenodeoxycholic Acid; Cholic Acids; Chromatography, Thin Layer; Deoxycholic Acid; Disease Models, Animal; Enterobacteriaceae Infections; Gallbladder; Liver; Muscle, Smooth; Perfusion; Pressure; Sodium; Sodium Chloride; Spasm; Time Factors | 1973 |
Early changes in bile composition and gallstone formation induced by a high cholesterol diet in prairie dogs.
Topics: Animals; Bile; Bile Acids and Salts; Chenodeoxycholic Acid; Cholelithiasis; Cholesterol; Cholesterol, Dietary; Cholic Acids; Crystallization; Diet, Atherogenic; Disease Models, Animal; Liver; Male; Phospholipids; Rodentia; Time Factors; Triglycerides | 1974 |